Dr. Reddy's has launched Toripalimab (Zytorvi) in India, marking a significant advancement in cancer treatment. Toripalimab is claimed to be the first and only globally approved immuno-oncology drug for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), a rare head and neck cancer. This launch makes India the third country to have access to this next-generation PD-1 inhibitor. Clinical studies have demonstrated that combining Toripalimab with standard chemotherapy reduces the risk of disease progression or death by 48%. It is also approved as a monotherapy for patients with disease progression after platinum-based chemotherapy, addressing a critical unmet need for Indian patients.

Toripalimab is a PD-1 inhibitor approved for RM-NPC, now launched in India.